Everly Bio has developed a non-invasive molecular sperm analysis test that uses machine learning to provide holistic decision support in fertility care. Everly Bio completed assay validation study, and now planning a US clinical pilot and exploring partnerships with a CLIA lab for commercialization.

Everly Bio's platform is also designed to support a broader roadmap, including non-invasive molecular embryo-selection tools.